title: P2Y-receptor regulates size of endothelial cells in an intracellular Ca2+ dependent manner.
abstract: The effects of P2 receptor agonists on cell size and intracellular calcium levels, [Ca(2+)](i), was investigated using cultured endothelial cells isolated from the caudal artery of male Wistar rats. Cell size and [Ca(2+)](i) were measured using a phase-contrast and fluorescent confocal microscopic image analyzer and a Calcium Green fluorescence probe. P2Y receptor agonists, 2-methylthio ATP (2meS-ATP), ADP, UTP and ATP decreased the cell size and increased [Ca(2+)](i) in endothelial cells from rat caudal artery. However, alpha,beta-methylene ATP, a P2X receptor agonist, did not induce these responses. The decrease in size and the increase in [Ca(2+)](i), by 2meS-ATP were blocked by PPADS (P2-antagonist), suramin (P2-antagonist), thapsigargin (Ca(2+) pump inhibitor) and U-73122 (phospholipase C inhibitor). The present results show that activation of P2Y receptors, not P2X receptors, induces a decrease in cell size and an increase in [Ca(2+)](i), and the pharmacological properties of these two responses are the same. We concluded that the size of endothelial cells is regulated by P2Y receptors via intracelluar Ca(2+) derived from Ca(2+) stores.
authors.affiliation: Department of Pharmacology, School of Pharmaceutical Sciences, Mukogawa Women's University, 663-8179, Nishinomiya, Japan.
authors.forename: Naoko
authors.initials: N
authors.lastname: Tanaka
authors.forename: Kumiko
authors.initials: K
authors.lastname: Kawasaki
authors.forename: Yoko
authors.initials: Y
authors.lastname: Kubota
authors.forename: Kazuki
authors.initials: K
authors.lastname: Nakamura
authors.forename: Michio
authors.initials: M
authors.lastname: Hashimoto
authors.forename: Masaru
authors.initials: M
authors.lastname: Kunitomo
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Shinozuka
mesh_terms: D000255:Adenosine Triphosphate / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000378:metabolism*; D048429:Cell Size / Q000187:drug effects*; D004730:Endothelium, Vascular / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004963:Estrenes / Q000494:pharmacology; D008297:Male; D009997:Osmotic Pressure; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D058910:Purinergic P2 Receptor Agonists; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives* / Q000494:pharmacology; D011760:Pyrrolidinones / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D018048:Receptors, Purinergic P2 / Q000187:drug effects / Q000502:physiology*; D013498:Suramin / Q000494:pharmacology; D019284:Thapsigargin / Q000494:pharmacology; D013873:Thionucleotides / Q000494:pharmacology
chemical_list: D004791:Enzyme Inhibitors; D004963:Estrenes; D010726:Phosphodiesterase Inhibitors; D058910:Purinergic P2 Receptor Agonists; D011760:Pyrrolidinones; D018048:Receptors, Purinergic P2; D013873:Thionucleotides; C060229:1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione; C077792:pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid; D011732:Pyridoxal Phosphate; D013498:Suramin; D019284:Thapsigargin; D000255:Adenosine Triphosphate; D002118:Calcium; C008501:2-methylthio-ATP